Fanghou的AI卫生体系得到中国的认可,从而能够更广泛地用于管理慢性病。 Fangzhou’s AI health system gets Chinese approval, enabling wider use in managing chronic diseases.

Fanghou Inc. 已经为其以保健为重点的XingJie LLM获得中国正式的AI服务申报证书,这是AI驱动的慢性病管理工作的一个重要里程碑。 Fangzhou Inc. has received China’s official Generative AI Service Filing Certificate for its healthcare-focused XingJie LLM, marking a key milestone in its AI-driven chronic disease management efforts. 包括XJ LLM和XS LLM在内的双型系统支持在方州AI+H2H生态系统内对体重管理和皮丝虫病等条件进行个性化和主动式护理。 The dual-model system, including the XJ LLM and XS LLM, supports personalized, proactive care for conditions like weight management and psoriasis within Fangzhou’s AI+H2H ecosystem. 该档案在深圳发行,有助于在与主要制药公司的伙伴关系和截至2025年6月为超过5 200万用户和229 000名医生提供服务的平台的支持下,扩大AI动力保健服务的部署。 The filing, issued in Shenzhen, enables expanded deployment of AI-powered health services, backed by partnerships with major pharmaceutical companies and a platform serving over 52 million users and 229,000 physicians as of June 2025.